Psoriasis: A focus on upcoming oral formulations

L Rusiñol, E Carmona-Rocha, L Puig - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Targeted therapies have greatly improved the quality of life of patients with
psoriasis. Despite the extensive list of treatments available, multiple new drugs are being …

Treatment patterns, healthcare resource utilization, and costs in patients with moderate‐to‐severe psoriasis treated with systemic therapy in Japan: A retrospective …

Y Tada, H Kim, D Spanopoulos… - The Journal of …, 2022 - Wiley Online Library
The real‐world treatment landscape for patients with moderate‐to‐severe psoriasis
receiving systemic therapies in Japan is not well understood. This study describes the …

Circulating Monocytes Are Predictive and Responsive in Moderate-to-Severe Plaque Psoriasis Subjects Treated with Apremilast

EL Larson, DP DeMeo, AB Young… - Journal of Investigative …, 2024 - Elsevier
Monocytes play a critical role in the inflammation associated with psoriasis, and their
abnormalities have been reported as biomarkers of cardiovascular event risk, a psoriasis …

[PDF][PDF] Efficacy and safety of apremilast in a patient with paraneoplastic dermatomyositis with resistant skin disease

N Cabas, M Turina, S Pizzolitto… - Clinical and …, 2023 - clinexprheumatol.org
Sirs, management of cancer-associated dermatomyositis represents a challenge since
immunosuppressive agents are often contraindicated in association with chemotherapy for …

Terapijski pristup psorijazi–prvi dio: lokalni pripravci

I Lukežić, N Hlača, M Vičić - Medicina Fluminensis: Medicina …, 2024 - hrcak.srce.hr
Sažetak Psorijaza je imunološki posredovana kronična upalna bolest kože i zglobova.
Najčešći oblik psorijaze jest vulgarna ili kronična stacionarna psorijaza, a očituje se …